Kyle T. Mincham

Kyle T. Mincham

Auto-generated profile, based on publicly available information

Kyle T. Mincham

National Heart and Lung Institute, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
OKOrestis Katsoulis
Orestis Katsoulis
MTMarie Toussaint
Marie Toussaint
MJMillie M. Jackson
Millie M. Jackson
PMPatrick Mallia
Patrick Mallia
JFJoseph Footitt
Joseph Footitt
ASAran Singanayagam
Aran Singanayagam
Respiratory viruses are a major trigger of exacerbations in chronic obstructive pulmonary disease (COPD). Airway neutrophilia is a hallmark feature of stable and exacerbated COPD but roles played by neutrophil extracellular traps (NETS) in driving disease pathogenesis are unclear. Here, using human studies of experimentally-induced and naturally-occurring exacerbations we identify that rhinovirus infection induces airway NET formation which is amplified in COPD and correlates with magnitude of inflammation and clinical exacerbation severity. We show that inhibiting NETosis protects mice from immunopathology in a model of virus-exacerbated COPD. NETs drive inflammation during exacerbations through release of double stranded DNA (dsDNA) and administration of DNAse in mice has similar protective effects. Thus, NETosis, through release of dsDNA, has a functional role in the pathogenesis of COPD exacerbations. These studies open up the potential for therapeutic targeting of NETs or dsDNA as a strategy for treating virus-exacerbated COPD.

21 September 2021 in Immunology
Verified
Journal Article
Open access
PDF file
KMKyle T. Mincham
Kyle T. Mincham
NBNicoletta Bruno
Nicoletta Bruno
ASAran Singanayagam
Aran Singanayagam
RSRobert J. Snelgrove
Robert J. Snelgrove
Neutrophils are critical components of the body's immune response to infection, being loaded with a potent arsenal of toxic mediators and displaying immense destructive capacity. Given the potential of neutrophils to impart extensive tissue damage, it is perhaps not surprising that when augmented these cells are also implicated in the pathology of inflammatory diseases. Prominent neutrophilic inflammation is a hallmark feature of patients with chronic lung diseases such as chronic obstructive pulmonary disease, severe asthma, bronchiectasis and cystic fibrosis, with their numbers frequently associating with worse prognosis. Accordingly, it is anticipated that neutrophils are central to the pathology of these diseases and represent an attractive therapeutic target. However, in many instances, evidence directly linking neutrophils to the pathology of disease has remained somewhat circumstantial and strategies that have looked to reduce neutrophilic inflammation in the clinic have proved largely disappointing. We have classically viewed neutrophils as somewhat crude, terminally differentiated, insular and homogeneous protagonists of pathology. However, it is now clear that this does not do the neutrophil justice, and we now recognize that these cells exhibit heterogeneity, a pronounced awareness of the localized environment and a remarkable capacity to interact with and modulate the behaviour of a multitude of cells, even exhibiting anti‐inflammatory, pro‐resolving and pro‐repair functions. In this review, we discuss evidence for the role of neutrophils in chronic lung disease and how our evolving view of these cells may impact upon our perceived assessment of their contribution to disease pathology and efforts to target them therapeutically.

14 December 2019 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
JLJean Francois Lauzon‐Joset
Jean Francois Lauzon‐Joset
KMKyle T. Mincham
Kyle T. Mincham
AAAna P. Abad
Ana P. Abad
BSBraden P. Short
Braden P. Short
PHPatrick G. Holt
Patrick G. Holt
JLJonatan Leffler
Jonatan Leffler

24 September 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KMKyle T. Mincham
Kyle T. Mincham
NSNaomi M. Scott
Naomi M. Scott
JLJean-Francois Lauzon-Joset
Jean-Francois Lauzon-Joset
JLJonatan Leffler
Jonatan Leffler
Alexander LarcombeAlexander Larcombe
Alexander Larcombe
DSDeborah H. Strickland
Deborah H. Strickland
Chronic allergic inflammatory diseases are a major cause of morbidity, with allergic asthma alone affecting over 300 million people worldwide. Epidemiological studies demonstrate that environmental stimuli are associated with either the promotion or prevention of disease. Major reductions in asthma prevalence are documented in European and US farming communities. Protection is associated with exposure of mothers during pregnancy to microbial breakdown products present in farm dusts and unprocessed foods and enhancement of innate immune competence in the children. We sought to develop a scientific rationale for progressing these findings toward clinical application for primary disease prevention. Treatment of pregnant mice with a defined, clinically approved immune modulator was shown to markedly reduce susceptibility of their offspring to development of the hallmark clinical features of allergic airway inflammatory disease. Mechanistically, offspring displayed enhanced dendritic cell–dependent airway mucosal immune surveillance function, which resulted in more efficient generation of mucosal-homing regulatory T cells in response to local inflammatory challenge. We provide evidence that the principal target for maternal treatment effects was the fetal dendritic cell progenitor compartment, equipping the offspring for accelerated functional maturation of the airway mucosal dendritic cell network following birth. These data provide proof of concept supporting the rationale for developing transplacental immune reprogramming approaches for primary disease prevention.

4 November 2022 in Cytometry Part A
Verified
Journal Article
Open access
KMKyle T. Mincham
Kyle T. Mincham
RSRobert J. Snelgrove
Robert J. Snelgrove
This 25‐parameter, 22‐color full spectrum flow cytometry panel was designed and optimized for the comprehensive enumeration and functional characterization of innate lymphoid cell (ILC) subsets in mouse tissues. The panel presented here allows the discrimination of ILC progenitors (ILCP), ILC1, ILC2, NCR+ ILC3, NCR− ILC3, CCR6+ lymphoid tissue‐inducer (LTi)‐like ILC3 and mature natural killer (NK) cell populations. Further characterization of ILC and NK cell functional profiles in response to stimulation is provided by the inclusion of subset‐specific cytokine markers, and proliferation markers. Development and optimization of this panel was performed on freshly isolated cells from adult BALB/c lungs and small intestine lamina propria, and ex vivo stimulation with phorbol 12‐myrisate 13‐acetate, ionomycin, and pro‐ILC activating cytokines.

1 May 2017 in Mucosal Immunology
Verified
Journal Article
Closed access
NSN.M. Scott
N.M. Scott
JLJean-Francois Lauzon-Joset
Jean-Francois Lauzon-Joset
AJA.C. Jones
A.C. Jones
KMK.T. Mincham
K.T. Mincham
NTN.M. Troy
N.M. Troy
DSD.H. Strickland
D.H. Strickland